Eliglustat
Glucosylceramide Synthase Inhibitor — ALIMENTARY TRACT AND METABOLISM
Also known as: cerdelga, eliglustat tartrate, Genz-112638, Genz-99067
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Eliglustat is an ofp drug in the Glucosylceramide Synthase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors, Glucosylceramide Synthase Inhibitors and P-Glycoprotein Inhibitors. DrugCentral lists 1 molecular target, including UGCG. Recorded indications include Glucosylceramide beta-glucosidase deficiency.
- Approval status: ofp (first approved 2014 by the FDA).
- Drug class: Glucosylceramide Synthase Inhibitor.
- Mechanism of action: Cytochrome P450 2D6 Inhibitors; Glucosylceramide Synthase Inhibitors; P-Glycoprotein Inhibitors.
- Molecular targets: UGCG (1 listed in DrugCentral).
- Indications: Glucosylceramide beta-glucosidase deficiency.
- ATC code: A16AX10 (Various alimentary tract and metabolism products).
- Molecular formula: C23H36N2O4; molecular weight 404.55 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Glucosylceramide beta-glucosidase deficiency
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 2D6 Inhibitors; Glucosylceramide Synthase Inhibitors; P-Glycoprotein Inhibitors |
|---|---|
| Established pharmacologic class | Glucosylceramide Synthase Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Ceramide glucosyltransferase | UGCG | inhibitor | IC50 6.83 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-11-20 | EMA | — | Genzyme Europe BV | |
| 2014-08-19 | FDA | — | GENZYME CORP |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A16AX10 | ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CYP2D6 · Testing Required
- FDA label: CYP2D6 · Testing Required
- HCSC label: CYP2D6 · Testing Required
- PMDA label: CYP2D6 · Testing Required
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Product dose omission in error | 514.5 |
| Weight increased | 271.7 |
| Weight decreased | 187.9 |
| Product dose omission issue | 75.3 |
| Chitotriosidase increased | 66.0 |
| Intentional dose omission | 57.2 |
| Bone pain | 50.9 |
| Dyspepsia | 50.0 |
| COVID-19 | 39.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Eliglustat is on its molecule page.
| Molecular formula | C23H36N2O4 |
|---|---|
| Molecular weight | 404.55 g/mol |
| CAS number | 491833-29-5 |
| InChIKey | FJZZPCZKBUKGGU-AUSIDOKSSA-N |
| PubChem CID | 23652731 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Eliglustat used for?
DrugCentral lists the following indications for Eliglustat: Glucosylceramide beta-glucosidase deficiency.
How does Eliglustat work?
Eliglustat is classified as Cytochrome P450 2D6 Inhibitors, Glucosylceramide Synthase Inhibitors and P-Glycoprotein Inhibitors; its molecular targets in DrugCentral include UGCG (inhibitor).
When was Eliglustat first approved?
Eliglustat was first approved by the FDA in 2014.
What drug class does Eliglustat belong to?
Eliglustat is in the Glucosylceramide Synthase Inhibitor class.
What is the chemical formula of Eliglustat?
Eliglustat has the molecular formula C23H36N2O4 and a molecular weight of 404.55 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4834 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2110588 — compound record and bioactivity
- PubChem CID 23652731 — chemical identifiers
- DrugBank DB09039 — drug record
- FDA UNII DR40J4WA67 — substance identity
- DailyMed: FDA labels for Eliglustat — current prescribing information (label search)
- UniProt Q16739 (UGCG) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.